Description
The NLDC-145 monoclonal antibody specifically recognizes CD205 which is also known as Dendritic and thymic Epithelial Cells, 205 kDa (DEC-205) or Lymphocyte antigen 75 (Ly-75). CD205 (DEC-205) is a ~205 kDa type 1 transmembrane glycoprotein that is encoded by Ly75 which belongs to the mannose receptor family within the C-type lectin superfamily. The extracellular region contains an N-terminal cysteine-rich domain followed by a fibronectin type II domain, 10 C-type lectin-like domains, a transmembrane region and cytoplasmic tail with an internalization sequence. CD205 (DEC-205) is highly expressed on both CD8+ and CD103+ dendritic cell subsets and Langerhans cells. It is variably expressed by some other dendritic cell types, Gr1+ bone marrow cells, B cells, T cells, thioglycolate-elicited macrophages, granulocytes, mucosal and thymic cortical epithelial cells, and brain endothelial cells. CD205 (DEC-205) serves as a pattern recognition receptor that functions as a recycling endocytic receptor. It participates in the cellular processing, presentation, and cross-presentation of foreign or self-antigens to initiate immunity or tolerance, respectively. CD205 (DEC-205) can reportedly serve as a promising target for immunotherapy including DC-targeted vaccination using anti-CD205 (DEC-205) monoclonal antibody conjugated with antigen for T cell activation.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. BD Horizon Brilliant Violet 510 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
